Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Evogene ( (EVGN) ) has provided an announcement.
On May 18, 2026, Evogene announced that its subsidiary Ag Plenus and Bayer Ag mutually agreed to terminate their joint herbicide development project after concluding that the APTH1 target protein failed to meet required product criteria. The termination, effective the same day, ends the collaboration but returns all licensed assets, including the APTH1 protein target and related active molecules, to Ag Plenus, potentially allowing Evogene’s subsidiary to repurpose or redirect these assets in future crop protection initiatives.
The project’s discontinuation underscores the technical and commercial hurdles in discovering novel herbicide modes of action, even when partnering with a major industry player like Bayer. While the end of this specific collaboration may temper near-term expectations around this herbicide program, the reversion of intellectual property and molecule rights to Ag Plenus preserves strategic optionality for Evogene and its stakeholders, who may view the regained assets as a platform for alternative development paths or new partnerships.
The most recent analyst rating on (EVGN) stock is a Buy with a $2.25 price target. To see the full list of analyst forecasts on Evogene stock, see the EVGN Stock Forecast page.
Spark’s Take on EVGN Stock
According to Spark, TipRanks’ AI Analyst, EVGN is a Neutral.
The score is held down primarily by weak financial performance (persistent losses, heavy cash burn, negative equity, and declining revenue). Technicals also reflect a downtrend with negative momentum. The earnings call provides partial support through sustained cost cuts and near-term liquidity actions, but top-line weakness and one-time items keep overall risk elevated.
To see Spark’s full report on EVGN stock, click here.
More about Evogene
Evogene Ltd. is an Israel-based biotechnology company focused on leveraging computational biology and artificial intelligence to develop innovative products in agriculture and life sciences. Through its subsidiaries, including Ag Plenus Ltd., the company targets crop protection solutions such as novel herbicides, positioning itself within the global agricultural technology and crop input markets.
Average Trading Volume: 100,310
Technical Sentiment Signal: Sell
Current Market Cap: $7.25M
For a thorough assessment of EVGN stock, go to TipRanks’ Stock Analysis page.